Stemline Therapeutics (STML)

[biocqr]

Stemline Therapeutics target raised to $70 at Aegis Capital (29.14 -1.12)

Aegis Capital raises their STML tgt to $70 from $40. Co has reported favorable preclinical data for its lead drug candidate, SL-401, in areas such as multiple myeloma and chronic myelogenous leukemia (CML). In firm's view, market authorization for SL-401 in MM and additional niche hematological malignancies on top of blastic plasmacytoid dendritic cell neoplasm and acute myeloid leukemia could drive peak sales potential from $800mm to over $3bn. Further, Stemline's follow-up candidate to SL-401, known as SL-501, is a variant interleukin-3-diphtheria toxin fusion protein that could be used to target CML as a new product.


Read more: http://www.briefing.com/InPlayEq/InPlay/InPlayDual.htm#ixzz2jEBkpn66